The Study
Abstract A009: AFNT-111: A novel TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V
This study is like testing a new toy in a lab and seeing if it can break a plastic block. It works on the block in the lab and in a toy mouse, but we don’t know if it would work on a real kid’s toy yet. We can’t say it will fix anything in real life.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists made special immune cells that can recognize a specific cancer-causing mutation (KRASG12V) and destroy cells with it, while ignoring healthy cells.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 512 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this could help treat cancers like pancreatic, lung, or colorectal cancer that often have this mutation and don't respond well to current drugs.
- 2The engineered cells killed cancer cells with the KRASG12V mutation in lab tests and shrank tumors in mice; they did not attack healthy human cells or unrelated cells.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Molecular Cancer Research
Year
2023
Authors
Michele M. Hoffmann, Xingyue He, C. Black, J. Francis, J. Parsons, Christian Roy, Jinsheng Liang, Hongjin Qu, Martin Campbell, T. Sewastianik, Jessica Webb, A. Chapuis, Thomas M. Schmitt, P. Greenberg, D. Hallet, Markus P. Vallaster, Piotr Pierog, Gary S. Shapiro, H. Lam, L. Vincent
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.